A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer

Carmelo Tibaldi, Editta Baldini, Sergio Ricci, Pier Franco Conte

Research output: Contribution to journalArticle

Abstract

The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demonstrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifos-famide 3 gr/sqm in day 1, Vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 μg total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52% of the courses and was given at 75% and 50% of the planned dose in 11% and 4.3% respectively; G-CSF was administered in 65.2% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose vinorelbine on day 15 was emitted or reduced in the majority of the cycles.

Original languageEnglish
Pages (from-to)3213-3215
Number of pages3
JournalAnticancer Research
Volume16
Issue number5 B
Publication statusPublished - Sep 1996

Fingerprint

Ifosfamide
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cisplatin
Outpatients
Granulocyte Colony-Stimulating Factor
Neutropenia
Febrile Neutropenia
Neutrophils
vinorelbine
Incidence

Keywords

  • Cisplatin
  • Ifosfamide
  • NSCLC
  • Weekly vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer. / Tibaldi, Carmelo; Baldini, Editta; Ricci, Sergio; Conte, Pier Franco.

In: Anticancer Research, Vol. 16, No. 5 B, 09.1996, p. 3213-3215.

Research output: Contribution to journalArticle

@article{c189bf9d21094496aa67bc04dcfae5ea,
title = "A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer",
abstract = "The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demonstrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifos-famide 3 gr/sqm in day 1, Vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 μg total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63{\%} of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52{\%} of the courses and was given at 75{\%} and 50{\%} of the planned dose in 11{\%} and 4.3{\%} respectively; G-CSF was administered in 65.2{\%} of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose vinorelbine on day 15 was emitted or reduced in the majority of the cycles.",
keywords = "Cisplatin, Ifosfamide, NSCLC, Weekly vinorelbine",
author = "Carmelo Tibaldi and Editta Baldini and Sergio Ricci and Conte, {Pier Franco}",
year = "1996",
month = "9",
language = "English",
volume = "16",
pages = "3213--3215",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer

AU - Tibaldi, Carmelo

AU - Baldini, Editta

AU - Ricci, Sergio

AU - Conte, Pier Franco

PY - 1996/9

Y1 - 1996/9

N2 - The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demonstrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifos-famide 3 gr/sqm in day 1, Vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 μg total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52% of the courses and was given at 75% and 50% of the planned dose in 11% and 4.3% respectively; G-CSF was administered in 65.2% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose vinorelbine on day 15 was emitted or reduced in the majority of the cycles.

AB - The combination of cisplatin and ifosfamide on day 1 plus vinorelbine on day 1 and 8, every 3 weeks, has demonstrated a high response rate and acceptable toxicities in advanced NSCLC patients. The present study was designed to analyse the feasibility and toxicity of a similar regimen in which vinorelbine was administered on a weekly basis in advanced NSCLC patients. The scheme consisted of cisplatin 80 mg/sqm, Ifos-famide 3 gr/sqm in day 1, Vinorelbine on day 8 and 15 was modified according to the absolute neutrophil count. Patients who experienced grade 3-4 neutropenia received G-CSF (300 μg total dose subcutaneously) from days 10 to 13 and from 17 to 20 of each subsequent course. Twelve patients were treated and forty-six courses were evaluable for toxicity. Grade 3-4 neutropenia was observed in 63% of the courses; 3 episodes of febrile neutropenia were recorded. Vinorelbine on day 15 was omitted in 52% of the courses and was given at 75% and 50% of the planned dose in 11% and 4.3% respectively; G-CSF was administered in 65.2% of the courses. This scheme is not feasible because of the high incidence of grade 3-4 neutropenia. In spite of G-CSF, the dose vinorelbine on day 15 was emitted or reduced in the majority of the cycles.

KW - Cisplatin

KW - Ifosfamide

KW - NSCLC

KW - Weekly vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0029841506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029841506&partnerID=8YFLogxK

M3 - Article

C2 - 8920792

AN - SCOPUS:0029841506

VL - 16

SP - 3213

EP - 3215

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -